Health Canada approves drug that treats sleep apnea in adults with obesity (opens original article in a new tab)

Health Canada has approved Zepbound, a weight-loss drug containing tirzepatide, for treating obstructive sleep apnea in adults with obesity. The drug works by reducing appetite and has shown significant improvement in reducing breathing interruptions during sleep. It is not a replacement for CPAP therapy and should be used with diet and exercise.

• Health Canada approved Zepbound for treating obstructive sleep apnea in adults with obesity
• Zepbound is a GLP-1 drug that reduces appetite through tirzepatide to promote weight loss
• Clinical trials showed 25-29 fewer breathing interruptions per hour for patients on tirzepatide